



Registered & Corporate Office:  
AMANTA HEALTHCARE LIMITED  
8<sup>th</sup> Floor, Shaligram Corporates, CJ Marg,  
Ambli, Ahmedabad-380058, Gujarat, INDIA.  
Tel.: 079 – 67777600  
Email: [info@amanta.co.in](mailto:info@amanta.co.in)  
Website: [www.amanta.co.in](http://www.amanta.co.in)

CIN: L24139GJ1994PLC023944

May 19, 2026

|  |   |
|--|---|
| To,<br>Sr. General Manager<br>Listing Department<br><b>BSE Limited</b><br>Phiroze Jeejeebhoy Towers,<br>Dalal Street, Mumbai – 400 001.<br><br>Scrip Code: <b>544502</b> | To,<br>Sr. General Manager<br><b>National Stock Exchange of India Limited</b><br>Exchange Plaza, C-1, Block G<br>Bandra Kurla Complex<br>Bandra (E), Mumbai – 400 051.<br><br>Trading Symbol: <b>AMANTA</b> |
|--|---|

Dear Sir/ Madam,

**Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") - Press Release**

With reference to the captioned subject, please find enclosed herewith Press Release on the Financial Results for the quarter and year ended March 31, 2026.

You are requested to take the same on your records.

Thanking you.

Yours sincerely,

**For AMANTA HEALTHCARE LIMITED**

**NIKHITA DINODIA**  
Company Secretary & Compliance Officer

**Encl.:** As above



**Amanta Healthcare Limited announces  
Q4 & FY26 Results**

**Consistent Revenue Momentum, 42% YoY Profit Growth in FY26  
Major Capacity Expansion in Progress**

**Ahmedabad, May 19<sup>th</sup>, 2026: Amanta Healthcare Limited (BSE: 544502, NSE: AMANTA)** today announced the unaudited financial results for the quarter ended March 31, 2026.

| Rs. in Cr.       | Q4FY26       | Q4FY25 | YoY %     | FY26          | FY25   | YoY%    |
|------------------|--------------|--------|-----------|---------------|--------|---------|
| Revenue          | <b>76.99</b> | 72.07  | 6.8%      | <b>287.68</b> | 274.71 | 4.7%    |
| Operating EBITDA | <b>16.61</b> | 17.49  | (5.0) %   | <b>63.23</b>  | 61.05  | 3.6%    |
| EBITDA Margin%   | <b>22%</b>   | 24%    | (200) bps | <b>22%</b>    | 22%    | -       |
| PAT              | <b>5.53</b>  | 4.32   | 28.0%     | <b>14.88</b>  | 10.5   | 41.7%   |
| PAT Margin%      | <b>7%</b>    | 6%     | 100 bps   | <b>5%</b>     | 4%     | 100 bps |

**Q4 & FY26 Key Highlights:**

- Sustained revenue trajectory:

Q4FY26 revenue stood at INR 77 cr, registering a 7% YoY growth, while FY26 revenue reached INR 288 cr, marking a 5% YoY increase, reflecting consistent growth.

- **Operational discipline sustains EBITDA margins:**

EBITDA for Q4FY26 came in at INR 17 cr with margins at 21%, while FY26 EBITDA increased 6.06% YoY to INR 63 cr, with margins improving YoY to 22%, highlighting effective cost control and operational efficiency.

- **Profitability strengthens on robust execution:**

Net Profit for Q4FY26 rose to INR 5.5 cr, up 28% YoY, while FY26 PAT grew 42% YoY to INR 15 cr, underscoring strong profitability momentum led by decreasing in finance cost.

- **Improving earnings quality reflected in margins:**

Q4FY26 PAT margin stood at 7%, while FY26 PAT margin stood at 5% compared to 4% for FY25 driven by operating leverage and margin normalization.

**Commenting on the performance for the quarter, Bhavesh Patel, Chairman & Managing Director, Amanta Healthcare Limited said,**

*“FY26 has been a year of consistent progress and disciplined execution for Amanta Healthcare. We reported revenue of ₹288 crore, reflecting a growth of 5% YoY. More importantly, PAT grew strongly by 42% YoY to ₹15 crore, supported by improved operating leverage and lower finance costs, highlighting the strengthening quality of our earnings. For the quarter as well on a YoY basis, the revenue stood at ₹77 crore, up 7% YoY, while PAT increased 28% YoY to ₹5.5 crore, reflecting continued momentum in profitability.*

*Going forward, our focus remains on scaling high-margin SteriPort and SVP capacities, expanding our presence across domestic and export markets, and improving operational efficiencies through strategic initiatives such as our captive solar power project. With differentiated manufacturing technologies, a growing product portfolio, and ongoing capacity expansion, we believe Amanta Healthcare is well-positioned to drive sustainable growth and create long-term value for all stakeholders”*

#### **ABOUT AMANTA HEALTHCARE LIMITED**

Amanta, a pharmaceutical company engaged in development, manufacturing, and marketing of sterile liquid products, including both large and small volume parenteral (LVPs and SVPs). Using advanced Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies, the Company serves six therapeutic segments with products such as IV fluids, diluents, ophthalmic and respiratory care, and irrigation solutions. The packaging includes a wide range of closure systems and container volumes from 2 ml to 1000 ml. Amanta is led by experienced Management including our Promoter & CMD – Mr. Bhavesh Patel, a Mechanical Engineer and master’s degree in management with more than 30 years of experience.

For more information, please visit: [www.amanta.co.in](http://www.amanta.co.in)

| <a href="#">Company contact</a>  | <a href="#">Investor Relations Team</a>   |
|--|---|
| Email: <a href="mailto:cs@amanta.co.in">cs@amanta.co.in</a> ,<br>Tel: 079 6777 7600<br><br>Amanta Healthcare Ltd.<br>8th Floor, Shaligram Corporates,<br>C. J. Marg, Ambli, Ahmedabad 380058 Gujarat,<br>India | Soumya Chhajer<br>Email- <a href="mailto:soumya@goindiaadvisors.com">soumya@goindiaadvisors.com</a><br>Mobile: +91-8619707750 |